Humasis Co. Ltd. (KOSDAQ:205470)
South Korea · Delayed Price · Currency is KRW 4,265.00
+120.00 (2.90%)
May 21, 2026, 3:30 PM KST
Humasis Revenue
In the year 2025, Humasis had annual revenue of 30.11B KRW with 18.49% growth. Humasis had revenue of 6.42B in the quarter ending December 31, 2025, a decrease of -46.09%.
Revenue
30.11B
Revenue Growth
+18.49%
P/S Ratio
3.12
Revenue / Employee
436.42M
Employees
69
Market Cap
93.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.11B | 4.70B | 18.49% |
| Dec 31, 2024 | 25.41B | 11.59B | 83.79% |
| Dec 31, 2023 | 13.83B | -457.45B | -97.07% |
| Dec 31, 2022 | 471.27B | 149.44B | 46.44% |
| Dec 31, 2021 | 321.83B | 276.11B | 603.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 1.51T |
| Ildong Holdings | 590.89B |
| ALTEOGEN | 215.86B |
| CKD Bio | 159.93B |
| DK Life Science | 130.34B |
| LabGenomics | 88.16B |